Jaypee Brothers
In Current Chapter
In All Chapters
X
Clear
X
GO
Normal
Sepia
Dark
Default Style
Font Style 1
Font Style 2
Font Style 3
Less
Normal
More
Diabetes
SN Chugh
UNIT 1:
Applied Anatomy and Physiology of Pancreas
GROSS ANATOMY OF THE PANCREAS
APPLIED PHYSIOLOGY OF THE PANCREAS
CARBOHYDRATE METABOLISM
GLUCOSE HOMEOSTASIS (Fig. 1.5)
GLUCOSE HOMEOSTASIS DURING FASTING
GLUCOSE HOMEOSTASIS DURING STARVATION AND EXERCISE
REGULATION OF INSULIN SECRETION
NORMAL INSULIN SECRETION AND PATTERN
INSULIN STRUCTURE AND C-PEPTIDE
INSULIN ACTIONS
ACTION OF OTHER PANCREATIC HORMONES
UNIT 2:
Diabetes: Prevalence, Types, Classification, Etiopathogenesis and Pathophysiology
PREVALENCE OF DIABETES MELLITUS—A PANDEMIC
TYPES OF DIABETES MELLITUS
CLASSIFICATION OF DM
ETIOPATHOGENESIS OF TYPE 1 DM
TYPE 2 DIABETES MELLITUS
ETIOPATHOGENESIS OF TYPE 2 DM
EVOLUTION OF TYPE 2 DM
PATHOPHYSIOLOGY OF TYPE 2 DM
BETA CELL DYSFUNCTION IN TYPE 2 DM
OBESITY AND TYPE 2 DM
HIGH RISK ABDOMINAL OBESITY AND ADEPOSINES
DYSLIPIDEMIA IN DIABETES
TREATMENT OF DYSLIPIDEMIA
HYPERTENSION AND DIABETES
METABOLIC SYNDROME (SYNDROME X, REAVEN'S SYNDROME)
COMPONENTS AND TREATMENT OF METABOLIC SYNDROME
UNIT 3:
Clinical Manifestations and Diagnosis of Diabetes Mellitus
CLINICAL MANIFESTATIONS OF TYPE 1 DIABETES MELLITUS
CLINICAL MANIFESTATIONS OF TYPE 2 DIABETES MELLITUS
CUTANEOUS MANIFESTATIONS OF DIABETES MELLITUS
DIAGNOSIS OF DIABETES MELLITUS
ORAL GLUCOSE TOLERANCE TEST
UNIT 4:
Treatment Goals, Modalities and Options
TREATMENT OF DIABETES MELLITUS
Treatment Options and Modalities (Fig. 4.2)
LIFESTYLE MODIFICATIONS
DIET IN DIABETICS
MEDICAL NUTRITION IN TYPE 1 AND TYPE 2 DM
EXERCISE IN DIABETES
EXERCISE PROGRAMS
Some Known Facts (Table 4.2)
Warm-up Phase (5 Minutes)
Cardiovascular Phase (20 Minutes)
Alternatives to Walking in Cardiovascular Phase (for a Minimum of 20 Minutes) (Fig. 4.7)
Cool-down Phase (5 Minutes)
Exercise Programs (Summary)
ORAL HYPOGLYCEMIC/ANTIDIABETIC DRUGS
INSULIN SECRETAGOGUES—SULFONYLUREAS (SUS)
CHOOSING A SULFONYLUREA
INSULIN SECRETAGOGUE—MEGLITINIDE DERIVATIVES
INSULIN SENSITIZERS/INSULIN SPARING DRUGS
BIGUANIDES—INSULIN SPARING DRUGS
ALPHA-GLUCOSIDASE INHIBITORS
ALPHA-GLUCOSIDASE INHIBITORS—A BETTER OPTION FOR MEAL STIMULATED GLUCOSE HIKE (Fig. 4.25)
COMBINATION THERAPY—CHOOSING ORAL AGENTS
ADD-ON-THERAPY WITH ORAL HYPOGLYCEMIC AGENTS (OHA) (Fig. 4.26)
FDA APPROVED OHA COMBINATION THERAPY
The Dependable Trio for Type II Diabetes (Fig. 4.27)
INSULINS
INSULIN PREPARATIONS
PHARMACOKINETICS OF INSULIN PREPARATIONS
INSULIN REGIMENS—MULTIPLE DOSAGE
INTENSIVE INSULIN THERAPY (BASAL-BOLUS STRATEGY)
PRACTICAL GUIDELINES FOR INSULIN THERAPY IN TYPE 2 DM
GUIDELINES FOR INSULIN THERAPY
I. Initiation of Basal Insulin (Glargine, Detemir, NPH) Recommendations (Fig. 4.36)
II. Advance Basal Insulin Plus Prandial Insulin at Main Meal
III. Advance Basal Insulin Plus Prandial Insulin with each Meal
INSULIN DELIVERY DEVICES AND INJECTION SITES
Needle and Syringe Method (Fig. 4.37A)
INDICATIONS OF INSULIN THERAPY
INSULIN PEN AND INSULIN PUMP DELIVERY DEVICES
Insulin Pump Therapy
INSULIN INFUSION PUMP THERAPY
INSULIN INFUSION PUMP DEVICE
INSULIN STORAGE
Important Points (Fig. 4.43)
INSULIN SIDE EFFECTS
SOCIAL AND SYSTEM RELATED BARRIER TO INSULIN
ORAL INSULIN
BEYOND INSULIN THERAPY
AMYLIN DEFICIENCY AND LOSS OF ITS EFFECTS
AMYLIN ANALOG—PRAMLINITIDE
INCRETIN AND INCRETINOMIMETICS
GLP-1 MIMETIC—EXENATIDE
DPP-4 INHIBITION
Inhibition of DPP-4 increases active GLP- 1
DPP-4 inhibition and glycemic control
DPP 4-Inhibitors
COMBINATION THERAPY: INSULIN PLUS OHA
FDA APPROVED INSULIN PLUS OHA
PARAMETERS OF GLYCEMIC CONTROL
SELF MONITORING OF BLOOD GLUCOSE
CONTINUOUS GLUCOSE MONITORING BY SENSOR
GLYCOSYLATED HEMOGLOBIN (HBA1C)
DIABETES AND SICK DAY MANAGEMENT
Management
Sick day management with insulin
Adjustment of Insulin Depending on Situation
PANCREATIC VS ISLET CELL TRANSPLANTATION
ISLET CELL TRANSPLANTATION
PRIMARY PREVENTION OF DIABETES
METHODS TO PREVENT TYPE 2 DM
PREVENTION OF DIABETIC COMPLICATIONS AND NEW-ONSET DIABETES BY ACE INHIBITORS
UNIT 5:
Diabetic Complications and Management
DIABETIC KETOACIDOSIS (DKA)
PATHOGENESIS, CLINICAL FEATURES AND DIAGNOSIS OF DKA
PRINCIPLES OF MANAGEMENT OF DKA
Fluid Replacement
Capillary Blood Glucose Measurement
Steps
Monitoring
HYPERGLYCEMIC HYPEROSMOLAR NONKETOTIC COMA (HHNKC)
Pathogenesis and Clinical Features of HHNKC
Treatment of HHNKC
LACTIC ACIDOSIS
Diagnosis and Treatment of Lactic Acidosis
HYPOGLYCEMIA IN DIABETES
DIAGNOSIS OF HYPOGLYCEMIA
ETIOPATHOGENESIS OF HYPOGLYCEMIA
Factors Responsible for Hypoglycemia in Diabetes
Clinical Features of Hypoglycemia
MANAGEMENT OF HYPOGLYCEMIA
DIABETIC ANGIOPATHY
DIABETIC NEPHROPATHY
Etiopathogenesis of DN
TREATMENT OF DIABETIC NEPHROPATHY (DN)
DIABETIC RETINOPATHY
Manifestations of Diabetic Retinopathy
Classification of Diabetic Retinopathy with Impact on Vision
DIABETIC NEUROPATHY
PATHOPHYSIOLOGY OF DIABETIC NEUROPATHY
CLASSIFICATION OF DIABETIC NEUROPATHY IS GIVEN IN
NEUROPATHIC PAIN IN DIABETIC NEUROPATHY
CLINICAL FEATURES OF DIABETIC POLYNEUROPATHY (DPNP)
GENERATION OF PAIN IN DIABETES
DIAGNOSIS OF DPNP
MANAGEMENT OF DIABETIC POLYNEUROPATHY
The Aim of Management
DRUGS TO RELIEVE DIABETIC NEUROPATHIC PAIN
CHOICE OF DRUG IN DPNP WITH COMORBIDITIES
DIABETIC GASTROPARESIS
MANAGEMENT OF DIABETIC GASTROPARESIS
Management Protocol
SEXUAL DYSFUNCTION IN DIABETES
EVALUATION FOR ERECTILE DYSFUNCTION (Fig. 5.31)
TREATMENT FOR SEXUAL DYSFUNCTION
Treatment Options
DIABETIC CYSTOPATHY (AUTONOMIC BLADDER)
ENDOTHELIAL DYSFUNCTION IN DIABETES
MECHANISMS OF ENDOTHELIAL DYSFUNCTION
DIABETIC MACROANGIOPATHY
DIABETES AND ATHEROSCLEROSIS
Mechanisms of Accelerated Atherosclerosis in Diabetes
RISK FACTORS AND EVALUATION OF DIABETIC COMPLICATIONS
CORONARY ATHEROSCLEROSIS
THROMBOGENESIS AND DIABETES
STABLE/UNSTABLE ANGINA
MYOCARDIAL INFARCTION IN DIABETES
HEART FAILURE (HF) IN DIABETES
HEART FAILURE PREDISPOSE TO DM
OCCLUSIVE PERIPHERAL VASCULAR DISEASE (OPVD)
DIABETIC FOOT
PATHOGENESIS, CARE AND MANAGEMENT OF DIABETIC FOOT
DIABETES AND INFECTIONS
TREATMENT OF HYPERTENSION IN DIABETES
GUIDELINES FOR TREATMENT OF HYPERTENSION IN DIABETES (FIG. 5.50)
TREATMENT OF DYSLIPIDEMIA IN DIABETES
TREATMENT OF COMBINED HYPERLIPIDEMIA
UNIT 6:
Other Aspects of Diabetes
GESTATIONAL DM
PREGESTATIONAL DIABETES MELLITUS
MANAGEMENT OF DIABETES IN PREGNANCY
INSULIN THERAPY IN DM WITH PREGNANCY
DIABETIC EDUCATIONA—TEAM WORK (FIG. 6.3)
CURRICULA FOR DIABETES SELF MANAGEMENT
GENETICS IN DM: DIABETES AND CHILD'S RISK
Type I Diabetes and Your Child
Genetic in Diabetes
Type 2 DM and Your Child
DIABETES AND DRIVING
Suggested Reading
INDEX
TOC
Index
×
Chapter Notes
Save
Clear